Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s traded shares stood at 3.39 million during the last session, with the company’s beta value hitting 2.16. At the close
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s traded shares stood at 14.5 million during the last session, with the company’s beta value hitting 2.20. At the close
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s traded shares stood at 1.53 million during the last session, with the company’s beta value hitting 2.20. At the close
In the latest trading session,, 0.55 million Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) shares changed hands as the company’s beta touched 2.20. With the company’s most
In last trading session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) saw 0.69 million shares changing hands with its beta currently measuring 2.20. Company’s recent per share
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) has a beta value of 2.21 and has seen 1.22 million shares traded in the last trading session. The company,
During the last session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s traded shares were 2.77 million, with the beta value of the company hitting 2.21. The 52-week
In today’s recent session, 0.31 million shares of the Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) have been traded, and its beta is 2.21. Most recently the
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s traded shares stood at 1.7 million during the last session, with the company’s beta value hitting 2.22. At the close
In the last trading session, 1.24 million Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) shares changed hands as the company’s beta touched 2.21. With the company’s per
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne
